{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:22:25Z","timestamp":1791829345352,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Clinical medical innovation guidance project of Hunan Provincial Science and Technology Department","award":["2021SK50928"],"award-info":[{"award-number":["2021SK50928"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    To preliminarily analyze the clinical efficacy and safety of PD-1 inhibitors as monotherapy or in combination with ruxolitinib (RUX) for adult Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) based on real-world retrospective data. A retrospective case series analysis was performed on clinical data of 4 adult EBV-HLH patients treated with sintilimab (a PD-1 inhibitor) alone or combined with RUX at the Department of Hematology, Hunan Provincial People\u2019s Hospital, from April 1, 2020 to February 1, 2024. Clinical efficacy, survival outcomes, dynamic changes of laboratory indicators and adverse reactions were observed. Among the 4 patients, 2 achieved complete remission (CR), 1 experienced treatment interruption due to non-adherence and was lost to follow-up, and 1 died of multi-organ failure induced by COVID-19, with a 1-year overall survival (OS) rate of 75.00%. All patients received sintilimab with a median treatment course of 9.5 cycles and a median infusion dose of 1900\u00a0mg; 3 patients were combined with RUX. After one cycle of treatment, the levels of alanine aminotransferase (ALT), aspartate transaminase (AST) and interleukin-10 (IL-10) decreased significantly, while white blood cell (WBC), hemoglobin (HGB) and platelet (PLT) levels increased significantly (all\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05). Ferritin (Ferr) returned to the normal range and fibrinogen (Fbg) showed an upward trend. The number of peripheral blood T, B and natural killer (NK) cells increased in 3 patients who completed lymphocyte subset detection. No drug-related severe adverse reactions of grade 3 or above were observed in all patients. PD-1 inhibitors alone or combined with RUX show preliminary favorable efficacy and high tolerability in the treatment of adult EBV-HLH, which can effectively improve blood cell levels, control inflammatory responses and increase clinical remission rates. However, large-sample prospective studies are required to verify the long-term efficacy due to the small sample size of this study.\n                  <\/jats:p>","DOI":"10.1007\/s10238-026-02136-0","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T07:17:10Z","timestamp":1775114230000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Exploratory study of PD-1 inhibitors with or without ruxolitinib for the treatment of adult EBV-associated hemophagocytic lymphohistiocytosis: a real-world data-based preliminary investigation"],"prefix":"10.1007","volume":"26","author":[{"given":"Zhao","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"issue":"3","key":"2136_CR1","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/ajh.23911","volume":"90","author":"ZK Otrock","year":"2015","unstructured":"Otrock ZK, Eby CS. Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis[J]. Am J Hematol. 2015;90(3):220\u20134.","journal-title":"Am J Hematol"},{"issue":"12","key":"2136_CR2","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1473-3099(07)70290-6","volume":"7","author":"NG Rouphael","year":"2007","unstructured":"Rouphael NG, Talati NJ, Vaughan C, et al. Infections associated with haemophagocytic syndrome[J]. Lancet Infect Dis. 2007;7(12):814\u201322.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"2136_CR3","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/s41467-022-28479-2","volume":"13","author":"J Wang","year":"2022","unstructured":"Wang J, Ge JS, Wang Y, et al. EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1[J]. Nat Commun. 2022;13(1):866.","journal-title":"Nat Commun"},{"issue":"1","key":"2136_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2018-02-833806","volume":"132","author":"A Carbone","year":"2018","unstructured":"Carbone A, Gloghini A, Carlo-Stella C. Are EBV-related and EBV-unrelated Hodgkin lymphomas different with regard to susceptibility to checkpoint blockade?[J]. Blood. 2018;132(1):17\u201322.","journal-title":"Blood"},{"issue":"13","key":"2136_CR5","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1182\/blood-2015-12-684399","volume":"127","author":"R Das","year":"2016","unstructured":"Das R, Guan P, Sprague L, et al. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis[J]. Blood. 2016;127(13):1666\u201375.","journal-title":"Blood"},{"issue":"3","key":"2136_CR6","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.hemonc.2017.07.002","volume":"12","author":"JH Sin","year":"2019","unstructured":"Sin JH, Zangardi ML. Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: First case report[J]. Hematol Oncol Stem Cell Ther. 2019;12(3):166\u201370.","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"12","key":"2136_CR7","doi-asserted-by":"publisher","first-page":"e630","DOI":"10.1016\/S2352-3026(19)30156-5","volume":"6","author":"A Ahmed","year":"2019","unstructured":"Ahmed A, Merrill SA, Alsawah F, et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial[J]. Lancet Haematol. 2019;6(12):e630\u20137.","journal-title":"Lancet Haematol"},{"issue":"24","key":"2136_CR8","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1182\/blood.2021014860","volume":"139","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Zhao YZ, Ma HH, et al. A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis[J]. Blood. 2022;139(24):3493\u2013504.","journal-title":"Blood"},{"issue":"4","key":"2136_CR9","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bjh.17331","volume":"193","author":"JS Wang","year":"2021","unstructured":"Wang JS, Zhang R, Wu XY, et al. Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory\/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial[J]. Br J Haematol. 2021;193(4):761\u20138.","journal-title":"Br J Haematol"},{"issue":"2","key":"2136_CR10","first-page":"165","volume":"44","author":"JY Wu","year":"2023","unstructured":"Wu JY, Xu B, Zhu XJ, et al. Treatment of chronic active Epstein-Barr virus infection with PD-1 inhibitors: report of 6 cases and literature review [J]. Chin J Hematol. 2023;44(2):165\u20138.","journal-title":"Chin J Hematol"},{"issue":"20","key":"2136_CR11","first-page":"1492","volume":"102","author":"Hematology Branch of Chinese Medical Doctor Association, Hematology Group of Chinese Medical Association Pediatrics Branch","year":"2022","unstructured":"Hematology Branch of Chinese Medical Doctor Association, Hematology Group of Chinese Medical Association Pediatrics Branch. Chinese Expert Alliance of Hemophagocytic syndrome. Chinese Guidelines for Diagnosis and Treatment of hemophagocytic syndrome (2022 edition)[J]. Chin Med J. 2022;102(20):1492\u20139.","journal-title":"Chin Med J"},{"issue":"6","key":"2136_CR12","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/0092-8674(86)90803-2","volume":"47","author":"N Raab-Traub","year":"1986","unstructured":"Raab-Traub N, Flynn K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation[J]. Cell. 1986;47(6):883\u20139.","journal-title":"Cell"},{"issue":"4","key":"2136_CR13","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/pbc.26308","volume":"64","author":"RA Marsh","year":"2017","unstructured":"Marsh RA, Jordan MB, Talano JA, et al. Salvage therapy for refractory hemophagocytic lymphohistiocytosis: A review of the published experience[J]. Pediatr Blood Cancer. 2017;64(4):543.","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2136_CR14","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/hon.960","volume":"29","author":"M Shabbir","year":"2011","unstructured":"Shabbir M, Lucas J, Lazarchick J, et al. Secondary hemophagocytic syndrome in adults: a case series of 18 patients in a single institution and a review of literature[J]. Hematol Oncol. 2011;29(2):100\u20136.","journal-title":"Hematol Oncol"},{"issue":"1","key":"2136_CR15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1182\/blood.2023021074","volume":"143","author":"JS Wang","year":"2024","unstructured":"Wang JS, Su M, Wei N, et al. Chronic active Epstein-Barr virus disease originates from infected hematopoietic stem cells[J]. Blood. 2024;143(1):32\u201341.","journal-title":"Blood"},{"issue":"20","key":"2136_CR16","first-page":"3840","volume":"31","author":"YR Wang","year":"2023","unstructured":"Wang YR, He JX, Geng Y, et al. Clinical features and prognosis of Epstein-Barr virus associated hemophagocytic syndrome [J]. Mod Oncol. 2023;31(20):3840\u20133.","journal-title":"Mod Oncol"},{"issue":"26","key":"2136_CR17","doi-asserted-by":"publisher","first-page":"5184","DOI":"10.1182\/blood-2013-04-495309","volume":"121","author":"CE Terrell","year":"2013","unstructured":"Terrell CE, Jordan MB. Perforin deficiency impairs a critical immunoregulatory loop involving murine CD8\u2009+\u2009T cells and dendritic cells[J]. Blood. 2013;121(26):5184\u201391.","journal-title":"Blood"},{"issue":"23","key":"2136_CR18","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1182\/blood.2018894618","volume":"133","author":"P La Rosee","year":"2019","unstructured":"La Rosee P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults[J]. Blood. 2019;133(23):2465\u201377.","journal-title":"Blood"},{"issue":"8","key":"2136_CR19","first-page":"566","volume":"46","author":"A Wei","year":"2019","unstructured":"Wei A. JAK-STAT pathway and hemophagic cell syndrome [J]. Int J Pediatr. 2019;46(8):566\u201370.","journal-title":"Int J Pediatr"},{"key":"2136_CR20","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.2147\/IDR.S372998","volume":"15","author":"YB Pi","year":"2022","unstructured":"Pi YB, Wang JS, Wang Z. Successful treatment of relapsed epstein-barr virus-associated hemophagocytic lymphohistiocytosis after Allo-HSCT with PD-1 blockade: a case report[J]. Infect Drug Resist. 2022;15:3751\u20136.","journal-title":"Infect Drug Resist"},{"issue":"6","key":"2136_CR21","first-page":"507","volume":"36","author":"XZ Zeng","year":"2015","unstructured":"Zeng XZ, Wei N, Wang YN, et al. Clinical efficacy and prognosis of 61 patients with EBV-associated hemophagocytic lymphohistiocytosis [J]. Chin J Hematol. 2015;36(6):507\u201310.","journal-title":"Chin J Hematol"},{"issue":"1","key":"2136_CR22","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/ijc.32490","volume":"146","author":"MZ Qiu","year":"2020","unstructured":"Qiu MZ, He CY, Lu SX, et al. Prospective observation: clinical utility of plasma Epstein-Barr virus DNA load in EBV-associated gastric carcinoma patients[J]. Int J Cancer. 2020;146(1):272\u201380.","journal-title":"Int J Cancer"},{"issue":"21","key":"2136_CR23","doi-asserted-by":"publisher","first-page":"5663","DOI":"10.1182\/blood-2010-09-305979","volume":"117","author":"K Sato","year":"2011","unstructured":"Sato K, Misawa N, Nie C, et al. A novel animal model of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in humanized mice[J]. Blood. 2011;117(21):5663\u201373.","journal-title":"Blood"},{"issue":"3","key":"2136_CR24","first-page":"219","volume":"31","author":"L Chen","year":"2018","unstructured":"Chen L, You Y, Zhang WJ. etc. Application of RUX in hemophagocytic syndrome[J]. J Clin Hematol. 2018;31(3):219\u201321.","journal-title":"J Clin Hematol"},{"issue":"1","key":"2136_CR25","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/ijlh.13736","volume":"44","author":"LY Xu","year":"2022","unstructured":"Xu LY, Guo XF, Guan HZ. Serious consequences of Epstein-Barr virus infection: Hemophagocytic lymphohistocytosis[J]. Int J Lab Hematol. 2022;44(1):74\u201381.","journal-title":"Int J Lab Hematol"},{"issue":"11","key":"2136_CR26","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1182\/blood.2019003886","volume":"135","author":"PP Liu","year":"2020","unstructured":"Liu PP, Pan XY, Chen C, et al. Nivolumab treatment of relapsed\/refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults[J]. Blood. 2020;135(11):826\u201333.","journal-title":"Blood"},{"issue":"9927","key":"2136_CR27","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/S0140-6736(13)61048-X","volume":"383","author":"M Ramos-Casals","year":"2014","unstructured":"Ramos-Casals M, Brito-Zeron P, Lopez-Guillermo A, et al. Adult haemophagocytic syndrome[J]. Lancet. 2014;383(9927):1503\u201316.","journal-title":"Lancet"},{"issue":"3","key":"2136_CR28","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.jaip.2018.11.050","volume":"7","author":"KA Risma","year":"2019","unstructured":"Risma KA, Marsh RA. Hemophagocytic lymphohistiocytosis: clinical presentations and diagnosis[J]. J Allergy Clin Immunol Pract. 2019;7(3):824\u201332.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2136_CR29","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/1750-1172-8-168","volume":"8","author":"L Dotta","year":"2013","unstructured":"Dotta L, Parolini S, Prandini A, et al. Clinical, laboratory and molecular signs of immunodeficiency in patients with partial oculo-cutaneous albinism[J]. Orphanet J Rare Dis. 2013;8:168.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"2136_CR30","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1080\/10428190290026240","volume":"43","author":"J Sumegi","year":"2002","unstructured":"Sumegi J, Seemayer TA, Huang D, et al. A spectrum of mutations in SH2D1A that causes X-linked lymphoproliferative disease and other Epstein-Barr virus-associated illnesses[J]. Leuk Lymphoma. 2002;43(6):1189\u2013201.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2136_CR31","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/bjh.12293","volume":"161","author":"GN Usmani","year":"2013","unstructured":"Usmani GN, Woda BA, Newburger PE. Advances in understanding the pathogenesis of HLH[J]. Br J Haematol. 2013;161(5):609\u201322.","journal-title":"Br J Haematol"},{"issue":"1","key":"2136_CR32","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s13023-023-02861-9","volume":"18","author":"R Chen","year":"2023","unstructured":"Chen R, Lin Q, Zhu Y, Shen Y, Xu Q, Tang H, Cui N, Jiang L, Dai X, Chen W, Li X. Sintilimab treatment for chronic active Epstein-Barr virus infection and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children. Orphanet J Rare Dis. 2023;18(1):297.","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"2136_CR33","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1007\/s00277-023-05476-z","volume":"102","author":"Y Xu","year":"2023","unstructured":"Xu Y, Li W, Gan J, He X, Huang X. An analysis of sintilimab combined with ruxolitinib as compassionate therapy for 12 adults with EBV-associated hemophagocytic lymphohistiocytosis. Ann Hematol. 2023;102(12):3325\u201333.","journal-title":"Ann Hematol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02136-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02136-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02136-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:23:02Z","timestamp":1781644982000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02136-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2136"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02136-0","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"2 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study has been approved by the Medical Ethics Committee of Hunan Provincial People\u2019s Hospital, with research ethics approval numbers [2023] -35.2.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all patients or their legal representatives for participation in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Written informed consent for publication of their clinical details and clinical images was obtained from the patient.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"211"}}